Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2021

$3,495.00

Essential Benchmark Data for Dealmakers - The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2021 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

Publication date
October 2021
Number of pages
500+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP2013

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

 

This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2021.

 

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

 

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010, including a summary of the recent literature on the subject.

 

Chapter 3 provides an average benchmark royalty rates. The chapter includes numerous tables and figures summarizing the benchmark royalty rates by stage of development, therapy area and technology area.

 

Chapter 4 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.

 

Chapter 5 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.

 

Chapter 6 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

 

In addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

 

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

 

The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.

 

Key benefits

 

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 -2021 provides the reader with the following key benefits:

 

  • In-depth understanding of royalty rate partnering deal trends since 2010
  • Analysis of the structure of royalty clauses with real life case studies
  • Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release
  • Comprehensive access to actual partnering deal contracts entered into by the world’s life science companies where a royalty rate is disclosed
  • Insight into the royalty terms included in a licensing agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.       

 

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 includes:

 

  • Trends in royalty rates in the biopharma industry since 2010
  • Analysis of royalty rate clause structure
  • Case studies of real-life licensing deals which disclose royalty rates
  • Comprehensive listing of licensing deals which disclose royalty rates since 2010
  • Access to licensing contract documents which disclose royalty rates
  • The leading licensing deals by royalty rate value since 2010
  • Most active royalty rate disclosures since 2010

 

In Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 available deals and contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

 

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

 

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise royalty rates granted?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 provides the reader with the following key benefits:

 

  • In-depth understanding of royalty rate partnering deal trends since 2010
  • Analysis of the structure of royalty clauses with real life case studies
  • Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release
  • Comprehensive access to actual partnering deal contracts entered into by the world’s life science companies where a royalty rate is disclosed
  • Insight into the royalty terms included in a licensing agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2021 is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.       

 

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2021 includes:

 

  • Trends in royalty rates in the biopharma industry since 2010
  • Analysis of royalty rate clause structure
  • Case studies of real-life licensing deals which disclose royalty rates
  • Comprehensive listing of licensing deals which disclose royalty rates since 2010
  • Access to licensing contract documents which disclose royalty rates
  • The leading licensing deals by royalty rate value since 2010
  • Most active royalty rate disclosures since 2010

 

In Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2021 available deals and contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

 

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand. 

Executive Summary

 

Chapter 1 – Introduction

 

1.1. What are royalties?

1.2. History of royalty rates

1.3. Royalties in pharma and biotech

1.4. Royalties versus revenue share

1.5. Overview of the report

 

Chapter 2 – An overview of pharma and biotech royalty rates

 

2.1. Trends in royalty rates 2010 - 2021

2.2. Royalty rate disclosure in pharma and biotech

2.3. How do revenue shares figure?

2.4. A review of recent literature

2.5. Royalty rates in the future

 

Chapter 3 – Average royalty rates for pharma and biotech partnering

 

3.1. Royalty rates in early stage deals

3.2. Royalty rates by stage of development

3.3. Royalty rates by therapy area

 

Chapter 4 – The royalty clause in pharma and biotech deals

 

4.1. Partnering agreement structure

4.2. Structure of a typical royalty clause

4.3. Example royalty clauses

4.3.1. Case study 1: Merck Serono-Opexa Therapeutics

4.3.2. Case study 2: Aradigm - Grifols

4.3.3. Case study 3: Forect Laboratories - Trevena

4.3.4. Case study 4: Sage Therapeutics – University of California

 

Chapter 5 – Companies actively disclosing royalty rates

 

5.1. Twenty five most active companies in disclosing royalty rates

5.2. Top partnering deals by royalty rate

5.3. The role of bigpharma and bigbiotech in royalty rate disclosure

5.2. Top partnering deals by royalty rate

 

Chapter 6 – Royalty rate contract directory

 

Explore royalty rates within the deal contract document to gain greater insight

 

Appendices

 

Appendix 1 – Royalty rates in deals – by company A-Z

Appendix 2 – Royalty rates in deals - by therapy area

Appendix 3 – Royalty rates in deals - by stage of development at signing

Appendix 4 – Royalty rates in deals - by technology type

Appendix 5 – Royalty rate references

Appendix 6 – Resources

Appendix 7 – Deal type definitions

Appendix 8 – Example royalty rate deal contract document

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

TABLE OF FIGURES

 

Figure 1: Trends in pharma and biotech royalty rates, 2010-2021

Figure 2: Royalty rates in early stage at deal signing – 2010-2021

Figure 3: Royalty rates by phase of development at deal signing – 2010-2021

Figure 4: Royalty rates by therapy area – 2010-2021

Figure 5: Components of the partnering deal structure

Figure 6: Components of the partnering royalty clause

Figure 7: Most active companies disclosing royalty rate 2010-2021

Figure 8: Top deals by royalty rate 2010-2021

Figure 9: Deals disclosing revenue share 2010-2021

Figure 10: Online partnering resources

Figure 11: Deal type definitions

Figure 12: Licensing agreement for rhAAT – rEVO Biologics, LFB Biotechnologies

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3D Medicines, Abbott Laboratories, Abbvie, Ablynx, Abraxis BioScience, Acceleron Pharma, Acer Therapeutics, Acerus, Acrotech Biopharma, Actavis (acquired by Watson), Active Biomaterials, Acura Pharmaceuticals, Adamis Pharmaceuticals, Adaptimmune, Adeona Pharmaceuticals, Adial Pharmaceuticals, Aditx Therapeutics, Adlai Nortye, Aduro BioTech, Advanced Dosage Forms, Advaxis, Advirna, Aegerion Pharmaceutical, Aerie Pharmaceuticals, AEterna Zentaris, Afritex Medical Products, Agenus Bio, Agios Pharmaceuticals, AIT Therapeutics, Akcea Therapeutics, Akebia Therapeutics, Albert Einstein College of Medicine, Alchemia, Alder Biopharmaceuticals, Alector, Alexion Pharmaceuticals, Alexza Pharmaceuticals, Alfasigma, Alfa Wassermann, Allergan, Allergan (name changed from Actavis), Almirall, Alnylam Pharmaceuticals, Alpha Biopharma, Alternavida, Altman Enterprises, AltrazealTrading, Altum Pharmaceuticals, Alvogen, Amarantus BioSciences, American Type Culture Collection (ATCC), Amgen, Amherst Pharmaceuticals, Amorfix Life Sciences, Ampio Pharmaceuticals, Amylin Pharmaceuticals, Amyris, AnaBios, AnaptysBio, AnGes MG, Angion Biomedica, AnnaMed, Antibe Therapeutics, Antigen Express, Apricus Biosciences, Aquestive Therapeutics, Aradigm, Aratana Therapeutics, Arch Pharmalabs, Arctic Vision, Ardelyx, Arena Pharmaceuticals, Arrowhead Pharmaceuticals, Assembly Biosciences, Astellas Pharma, Astellas Pharma Europe, Asterias Biotherapeutics, AstraZeneca, Athenex, Atossa Genetics, Atreca, Audeo Oncology, Augmenta, Aurigene Discovery Technologies, Aurinia Pharmaceuticals, Authentic Brands Group, AVEO Oncology, Avita Therapeutics, Avivagen, Axovant Gene Therapies, Aytu BioScience, Azaya Therapeutics, Azure Biotech, Baker Brothers Investments, Baliopharm, BASF, Baxter International, Bayer Healthcare, Bayer Innovation, Baylor Research Institute, Belgian Volition, Bellerophon Therapeutics, Benitec Biopharma, Besins Healthcare, Beth Israel Deaconess Medical Center, BetterLife Pharma, Bharat Biotech, BIND Biosciences, BioCorRx, BioCryst Pharmaceuticals, Bioeq IP, Biogen, BioGene Technology, Biohaven Pharmaceutical Holding, BioInvent, BiolineRX, BioMarin Pharmaceutical, BioNovion, BioNTech, Biopharmex, BiopharmX, BioPorto, Bioprocess Capital Ventures, BioProspect, Biostem US, Biotech Investment, Biotechnology Value Fund, BioTime Acquisition, Bioton, Biovail, BioZone Laboratories, BioZone Pharmaceuticals, Bluebird Bio, Blueprint Medicines, BMV Medica, Boehringer Ingelheim, Braeburn Pharmaceuticals, BrainStorm Cell Therapeutics, Breathtec BioMedical, Bristol-Myers Squibb, Caleco Pharma, Calico, Can-Fite BioPharma, Cancer Prevention Pharmaceuticals, Cannassure Therapeutics, CanniMed Therapeutics, Canntab Therapeutics, Cannus Partners, Cantex Pharmaceuticals, Cara Therapeutics, Cardigant Medical, Cardium Therapeutics, CareFusion, Cary Pharmaceuticals, CASI Pharmaceuticals, Castle Creek Pharmaceuticals, Catalent, CB2 Therapeutics, Celdara Medical, Celgene, Cell Cure Neurosciences, Cel Sci, Celyad, Cereal Ingredients, Cerebain Biotech, Cerus, cGreen, Chi-Med, Chiesi Farmaceutici, Chimerix, Chong Kun Dang, Chongqing Jingdong Pharmaceutical, Cimtech, Cipher Pharmaceuticals, Cipla, Circassia, Clal Biotech, Clalit Health Services, Clearside Biomedical, Clemson University, Cleveland BioLabs, Clinigen, CMIC, CNS Pharmaceuticals, Cocrystal Pharma, Coeptis Pharmaceuticals, CohBar, Cohen-McNiece Foundation, Coherus Biosciences, Colby Pharmaceuticals, Collegium Pharmaceuticals, Columbia Laboratories, Columbia University, Common Sense, Conatus Pharmaceuticals, Concile, Consilient Health, ContraFect, Coronado Biosciences, Cosmo Pharmaceuticals, CRISPR Therapeutics, Crucell, CSL, CTT Pharmaceutical, Cumberland Pharmaceuticals, Cures Within Reach, CureTech, Curis, Currax Pharmaceuticals, CURx Pharmaceuticals, Cutanea Life Sciences, Cypress Bioscience, Cytodyn, Cytori Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Dana-Farber Cancer Institute, Dance Biopharm, DAS Therapeutics, Defiante Farmaceutica, Denali Therapeutics, DepoMed, Derma Sciences, Dermavant Sciences, Dermin, Dianomi Therapeutics, Dicerna Pharmaceuticals, DNA Biomedical Solutions, Dr. Falk Pharma, Dr. Reddy's Laboratories, Dragonfly Therapeutics, Drugs for Neglected Diseases Initiative, DS Healthcare, Duke University, Dyax, Eagle Pharmaceuticals, Eagle Pharmaceuticals (US), Easton Pharmaceuticals, Echo Therapeutics, Ecology Coatings, Eddingpharm, Egalet, Eisai, Elencee, Eli Lilly, Elite Pharmaceuticals, Emergent BioSolutions, Emory University, Endocyte, Endo Pharmaceuticals, Enochian Biosciences, Entera Bio, Entest BioMedical, EnWave, Epizyme, Epocal, Esperion Therapeutics, Eternity Healthcare, Eureka Genomics, EUSA Pharma, Evolva, Exact Sciences, Exelixis, Eyevance, Fairview Health System, FasTrack Pharmaceuticals, Ferozsons Laboratories, Fibrocell Science, Forest Laboratories, Fosun Pharmaceutical, Fox Chase Chemical Diversity Center, Fresenius Kabi Pharmaceuticals, FSD Pharma, Fusion Pharmaceuticals, FusionVax, Galapagos, Galmed Pharmaceuticals, GE Healthcare, Genentech, Generex Biotechnology, Genevant Sciences, Genmab, Gentium, Genzyme, Geron, Gilead Sciences, GlaxoSmithKline, Glenmark Generics Inc USA, Glenmark Pharmaceuticals, Goldfinch Bio, Government of Israel, Gravocore, Grifols, GT Biopharma, Hai Kang Life, Hail First Pharma, Hainan Sihuan Pharmaceutical, Halo Labs, Halozyme Therapeutics, Hansen Medical, Health Canada, Health Discovery, Heat Biologics, Hefei Life Science, Hefei Tianhui Incubation of Technologies, HekaBio, HemoCleanse, Hemogenyx, HemPup, Hetero Labs, HIBM Research Group, Hikma Pharmaceuticals, Hoffmann La Roche, Hollister Biosciences, Hookipa Pharma, Horizon Pharma Inc, HyperGenomics, Icahn School of Medicine at Mount Sinai, Ice + Jam, IDC-GP Pharm, IDEAYA Biosciences, Idera Pharmaceuticals, Idorsia, Idun Pharmaceuticals, iMetabolic Biopharma, Immugenyx, ImmunityBio, Immunomedics, Immunomic, Immunovative Therapies, ImmVira, Impax Laboratories, Imprimis Pharmaceuticals, iNAP, Incuron, Incyte, Infinity Pharmaceuticals, Inhibitor Therapeutics, Innate Pharma, Innocoll, Innovate Biopharmaceuticals, Innovation Pharmaceuticals, Innovus Pharmaceuticals, INO Therapeutics, Inspiration Biopharmaceuticals, Instrumentation Laboratory, IntelGenx, IntelliCell BioSciences, Intellikine, Internet Marketing Consortium, Intrexon, Intuitive Surgical, Invekra, Inverness Medical Innovations, Ionis Pharmaceuticals, Ipsen, Iroko Pharmaceuticals, Ironwood Pharmaceuticals, Israeli National Authority for Technological Innovation, Itrom Pharmaceutical Group, Jaguar Health, Janssen Biotech, Janssen Pharmaceuticals, Jazz Pharmaceuticals, JFC Technologies, Jiangsu Alphamab, Jiangsu Lianhuan Pharmaceuticals, Jiangsu NHWA Pharmaceutical, John Morley Foods, Jubilant Life Sciences, Juniper Pharmaceuticals, Junshi Biosciences, Juventas Therapeutics, K2M, Kadmon Pharmaceuticals, KaloBios Pharmaceuticals, KemPharm, Kensey Nash, Kieran Murphy, Kinetic Concepts, Kiniksa Pharmaceuticals, Kitov Pharma, Klaria, Knighton Foods, Knight Therapeutics, Kodiak Sciences, Kraig Biocraft Laboratories, KVK-Tech, Kwang Dong Pharmaceutical, Kyowa Hakko Kirin, L1 Systems, Laboratories Acbel, Legend Biotech, Level Brands, LFB Biotechnologies, Lifestyle Delivery Systems, Ligand Pharmaceuticals, Lipidor, Lorna Linda University, Lubrizol, Lumenis, Lundbeck, Lung Therapeutics, MabCure, Macrogenics, Magenta Therapeutics, MainPointe, Mallinckrodt Pharmaceuticals, Marvanal, Marv Enterprises, Massachusetts General Hospital, Matrix Biomed, Mayne Pharma, McComb Foundation, McEwen Centre for Regenerative Medicine, Meda, Medica, Medica Avante, Medical Technologies Innovation Asia, Medicines Patent Pool Foundation, MediGene, Medigus, MedImmune, Medison Pharma, Medivation, Medivir, Medovex, MEI Pharma, Melmed, Memory Dx, Merck and Co, Merck KGaA, Merck Serono, Merus, Micromet, Mikah Pharma, Millennium, Mimi’s Rock, Ministry of Health, Labor and Welfare, Miraculins, Moderna Therapeutics, Moleculin Biotech, Mologen, Momenta Pharmaceuticals, Monopar Therapeutics, Morgan Stanley, MorphoSys, Mount Sinai Health System, MultiCell Immunotherapeutics, Munich Leukemia Laboratory, Mylan Laboratories, Mylan Pharmaceuticals, Myovant Sciences, NanoVibronix, NantCell, NantKwest, Nantong Jinghua Pharmaceutical, NantWorks, Napo Pharmaceuticals, Natac Biotech, Natco Pharmaceuticals, National Green Biomed, Nektar Therapeutics, Neogenomics, Nephrogenex, Nephros, Neurocrine Biosciences, NeuroRx, NeuroSigma, NeuroVive Pharmaceutical, NeuroVive Pharmaceutical Asia, NewLeaf Brands, Newsoara Biopharma, New York University, NexMed, Nextleaf Solutions, Nexvet, NGM Biopharmaceuticals, Nicox, Nordic Bioscience, Norgine, NorthStar Medical Radioisotopes, Notable Labs, Novadaq Technologies, NovaDel Pharma, Novan, Novan Therapeutics, Novartis, Novartis Vaccines and Diagnostics, Novocure, Novus Biologicals, Nucorion, Nurix, Nutech Medical, NutraOrigin, NXTGEN, Nymox Pharmaceutical, Oberland Capital, Ocugen, Oculus Innovative Sciences, Ocumension Therapeutics, Omeros, Oncologie, Oncolytics Biotech, OncoMed Pharmaceuticals, Onegevity, One Way Liver Genomics (OWL), Onxeo, Onyx Pharmaceuticals, Opexa Therapeutics, OptiBiotix, OptiNose, Oragenics, Oramed Pharmaceuticals, Orexigen Therapeutics, Organovo, Orgenesis, Orion, Orox Pharmaceuticals, OrthoCyte, Otsuka, OvaMed, Oxford BioMedica, Oxis Biotech, Oxygen Biotherapeutics, OxySure Systems, Pan-Provincial Vaccine Enterprise, Parnell Pharmaceuticals, Par Pharmaceutical, PDL BioPharma, Penwest Pharmaceuticals, Pernix Therapeutics, Perugia University, Pfenex, Pfizer, Pharmacyclics, PharmaCyte Biotech, PharmaMar, PharmaNova, Pharmastrip, Phosphagenics, Photocure ASA, Phusion Laboratoies, Phyto Nutricare, Pieris, Pipex Pharmaceuticals, Plandai Biotechnology, Pluristem Therapeutics, Portola Pharmaceuticals, Poseida Therapeutics, Pozen, PreMD, Premier Biomedical, Professional Compounding Centers of America, Progenics Pharmaceuticals, Prometic Life Sciences, ProQR Therapeutics, Prosidion, Protalix BioTherapeutics, Proteonomix, Prothena Biosciences, ProtoKinetix, Pulmatrix, Puma Biotechnology, QRxPharma, Quick Med Technologies, Quigley Corporation, Reata Pharmaceuticals, Recordati, Recro Pharma, RedHill Biopharma, Reedy Creek Investments, RegenaStem, Regeneron Pharmaceuticals, Relay Therapeutics, Relief Therapeutics, Relmada Therapeutics, RenalytixAI, ReNeuron, Replicel Life Sciences, Repligen, Resarci Therapeutics, Retrophin, rEVO Biologics, Revolution Medicines, Rigel Pharmaceuticals, RNL Bio, Roche, Rockefeller University, Roivant Sciences, Royalty Pharma, RST Biomedikal Sanayi, Ruthigen, RXi Pharmaceuticals, S2 Therapeutics, SACCO, Sage Therapeutics, Salix Pharmaceuticals, Sam Amer, Sandoz, Sanofi, Sanofi-Aventis, Sanofi-Pasteur, Santarus, Santen Pharmaceutical, Sanuwave Health, SA Pathology, Sarepta Therapeutics, Scopus BioPharma, Seattle Genetics, Seelos Therapeutics, Sekris Biomedical, Senetek, Sensory Cloud, Sermonix Pharmaceutical, Shanghai Pharmaceuticals Holdings, Sheba Medical Center, Shenzhen BioScien Pharmaceuticals, Shield Therapeutics, Shionogi, Shire Pharmaceuticals, Shore Therapeutics, Siemens Healthcare Diagnostics, Sigma-Tau, Sinclair Pharmaceuticals, Sinobiopharma, Sinopharm, Skinvera, Skyline Diagnostics, Solarvest BioEnergy, Soliance, Soligenix, Sorrento Therapeutics, Spectranetics, Spencer Pharmaceutical, Spinal USA, St. Jude Children's Research Hospital, STADA Arzneimittel, Stanford University, Stealth Therapeutics, Stellar Biotechnologies, St Jude Medical, Strongbridge Biopharma, Sucampo AG, Sunesis Pharmaceuticals, SuperNova Diagnostics, Swedish Orphan Biovitrum, Symbollon, Synergy Strips, Syntopix, Tactical Relief, Taiba, Takeda Pharmaceutical, Tango Therapeutics, Target Group, Tauriga Sciences, TB Alliance, TearLab, Technion Research and Development Foundation, Tesaro, Tetra Bio-Pharma, TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries, Texas A&M University, TFF Pharmaceuticals, Therakine, Theravance, Theravance Biopharma, The Regents of the University of California, Thorne Research, Threshold Pharmaceuticals, TiGenix, Tilray, Titterington Veterinary Services, Tiziana Life Sciences, Tocagen, TONIX Pharmaceuticals, Torii Pharmaceutical, TRACON Pharmaceuticals, Tramorgan, Transgene, Trellis Bioscience, Trevena, Trimedyne, Trimeris, TrovaGene, TTFactor, Turnstone Biologics, Tyme Technologies, Ultragenyx Pharmaceuticals, Uluru, Unigene Laboratories, UniQure, Universal Cells, University Health Network, University of Alberta, University of California, University of Central Florida Research Foundation, University of Colorado, University of Florida Research Foundation, University of Geneva, University of Missouri, University of Notre of Dame, University of Pennsylvania, University of Texas, University of Virginia, University of Western Sydney, University of Zurich, UOP, Uppsalagruppen Medical, Upstream Peripheral Technologies, UroGen Pharma, Valeant Pharmaceuticals, ValiPharma, Valneva, Valor Biotherapeutics, Vanderbilt University, Vasomune Therapeutics, Vaxent, VBL Therapeutics (dba), Veloxis Pharmaceuticals, Veracyte, Verenium, VeroScience, Vertex Pharmaceuticals, Vida Concepts, Vifor Pharma, ViiV Healthcare, Virbac, Viropharma, VistaGen Therapeutics, Vividion Therapeutics, VolitionRX, Voyager Therapeutics, Vyera Pharmaceuticals, Vyrix Pharmaceuticals, Watson Pharmaceuticals, WAVE Life Sciences, Wigen Biomedicine, Wisconsin Alumni Research Foundation, World Class Extractions, WPD Pharmaceuticals, WUGEN, Xbrane Bioscience, Xencor, Xlife Sciences, XTL Biopharmaceuticals, Xynomic Pharmaceuticals, Yale University, Yeda Research and Development Company, Yeugnam University, Yissum Research Development, ZAI Laboratory, Zalicus, Zenitech, Zenith Epigenetics, Ziopharm Oncology, ZS Pharma

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!